DNA Methylation and Transcript Variant Analysis of CDKN2A Exon 2 Despite High Sequence Identity with CDKN2B Exon 2
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136128 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Katja Zappe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: DNA Methylation, Exons, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase Inhibitor p15. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open-Access Publishing Fund of the University of Vienna.
Abstract (Originalsprache)
The tumor suppressor p16INK4a, encoded by CDKN2A, is frequently inactivated in cancer through genetic or epigenetic mechanisms. While promoter hypermethylation is the most common epigenetic cause, aberrant methylation of CDKN2A exon 2 has also been associated with various tumor types. However, analyzing DNA methylation of exon 2 is challenging due to its high sequence similarity with CDKN2B. We developed a pyrosequencing assay to analyze CpGs in CDKN2A exon 2, which was previously found to be hypermethylated in breast cancer. Our novel primer set enabled co-amplification of the homologous regions in CDKN2A, including CpGs 1–24, and CDKN2B CpGs 1–23. By quantifying the proportion of CDKN2A, we could accurately determine methylation levels for CpGs in CDKN2A exon 2. This method was applied to patient-derived glioma cells and commercial breast cancer cell lines. To reveal the role of exon 2 methylation in gene regulation, we additionally examined CDKN2AINK4a promoter methylation and expression at both mRNA and protein levels in breast cancer cell lines. We observed a range of (epi)genetic alterations, including homozygous deletions, transcript-specific expression, and exon 2 skipping. Our findings indicate that both promoter and exon 2 methylation contribute to regulation of CDKN2A expression. This novel method provides a valuable tool for future studies seeking a deeper understanding of CDKN2A regulation in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
- Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
ORCID-Profile: Katja Zappe, Petra Heffeter, Margit Cichna-Markl
Förderung
- Open-Access Publishing Fund of the University of Vienna
Zitieren
APA
Zappe, K., Jenik, A., Berger, D., Uhlik, L., Heffeter, P., & Cichna-Markl, M. (2025). DNA Methylation and Transcript Variant Analysis of CDKN2A Exon 2 Despite High Sequence Identity with CDKN2B Exon 2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136128
Vancouver
Zappe K, Jenik A, Berger D, Uhlik L, Heffeter P, Cichna-Markl M. DNA Methylation and Transcript Variant Analysis of CDKN2A Exon 2 Despite High Sequence Identity with CDKN2B Exon 2. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136128
BibTeX
@article{Zappe2025,
author = {Zappe, Katja and Jenik, Andreas and Berger, Daniel and Uhlik, Lukas and Heffeter, Petra and Cichna-Markl, Margit},
title = {DNA Methylation and Transcript Variant Analysis of CDKN2A Exon 2 Despite High Sequence Identity with CDKN2B Exon 2},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136128}
}
EUVIMED